Cited by 312Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.

Alpha‐Synuclein as a Biomarker for Parkinson's Disease

Open access

Atik, Anzari, Stewart, Tessandra, Zhang, Jing·2016·Brain Pathology

DOI 10.1111/bpa.12370PMC PMC6245641

Open this paper in CoChat — free account

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder, characterized pathologically by the presence of α‐synuclein (α‐syn)‐rich Lewy bodies. As clinical diagnosis of PD is challenging, misdiagnosis is common, highlighting the need for disease‐specific and early stage biomarkers. Both early diagnosis of PD and adequate tracking of disease progression could significantly improve outcomes for patients, particularly in regard to existing and future disease modifying treatments. Given its critical roles in PD pathogenesis, α‐syn may be useful as a biomarker of PD. The aim of this review is, therefore, to summarize the efficacy of tissue and body fluid α‐syn measurements in the detection of PD as well as monitoring disease progression. In comparison to solid tissue specimens and biopsies, biofluid α‐syn levels may be the most promising candidates in PD diagnosis and progression based on specificity, sensitivity and availability. Although α‐syn has been tested most extensively in cerebrospinal fluid (CSF), the relatively invasive procedure for collecting CSF is not suitable in most clinical settings, leading to investigation of plasma, blood and saliva as alternatives. The exploration of combined biomarkers, along with α‐syn, to improve diagnostic accuracy is also likely required.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/bpa.12370

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,174
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714

Flagged first, then by citations

Show all 119 references

Sorted by citations

T cells from patients with Parkinson’s disease recognize α-synuclein peptides
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017) · Nature · doi:10.1038/nature22815 · Cited by 866
The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies
Jo, M., Lee, S., Jeon, Y., Kim, S., Kwon, Y., & Kim, H. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00513-7 · Cited by 427
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D. P., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 384
Premotor, nonmotor and motor symptoms of Parkinson's Disease: A new clinical state of the art
Silva, A. B. R. L., de Oliveira, R. W. G., Diógenes, G. P., Aguiar, M. F. D. C., Sallem, C. C., Lima, M. P. P., Filho, L. B. D. A., de Medeiros, S. D. P., de Mendonça, L. L. P., Filho, P. C. D. S., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101834 · Cited by 252
Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid
Concha‐Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M., & Soto, C. A. (2023) · Nature Protocols · doi:10.1038/s41596-022-00787-3 · Cited by 263
Detection of neuron-derived pathological α-synuclein in blood
Kluge, A., Bunk, J., Schaeffer, E., Drobny, A., Xiang, W., Knacke, H., Bub, S., Lückstädt, W., Arnold, P., Lucius, R., et al. (2022) · Brain · doi:10.1093/brain/awac115 · Cited by 230
Reverse engineering Lewy bodies: how far have we come and how far can we go?
Fares, M. B., Jagannath, S., & Lashuel, H. A. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-00416-6 · Cited by 205
α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease
Cao, Z., Wu, Y., Liu, G., Jiang, Y., Wang, X., Wang, Z., & Feng, T. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.12.030 · Cited by 162
Plasma α-synuclein predicts cognitive decline in Parkinson’s disease
Lin, C., Yang, S., Horng, H. E., Yang, C., Chieh, J.-J., Chen, H.-H., Liu, B.-H., & Chiu, M. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314857 · Cited by 158
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features
Goldman, J. G., Andrews, H., Amara, A. W., Naito, A., Alcalay, R. N., Shaw, L. M. J., Taylor, P., Xie, T., Tuite, P., Henchcliffe, C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27232 · Cited by 149
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Iarkov, A., Barreto, G. E., Grizzell, J. A., & Echeverrı́a, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00004 · Cited by 146
The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses
Jan, A., Gonçalves, N. P., Vægter, C. B., Jensen, P. H., & Ferreira, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158338 · Cited by 133
Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer’s and Parkinson’s Diseases in Young Mexico City Residents
Calderón‐Garcidueñas, L., Ávila-Ramírez, J., Calderón‐Garcidueñas, A. L., González-Heredia, T., Acuña-Ayala, H., Chao, C., Thompson, C., Ramos, R. R., Cortés-González, V., Martínez-Martínez, L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160472 · Cited by 112
What Can We Learn About Human Disease from the Nematode C. elegans?
Apfeld, J., & Alper, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7471-9_4 · Cited by 116
Oligomeric α-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease
Agliardi, C., Meloni, M., Guerini, F. R., Zanzottera, M., Bolognesi, E., Baglio, F., & Clerici, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105185 · Cited by 106
Systemic Activation of Nrf2 Pathway in Parkinson's Disease
Petrillo, S., Schirinzi, T., Lazzaro, G. D., D’Amico, J., Colona, V. L., Bertini, E., Pierantozzi, M., Mari, L., Mercuri, N. B., Piemonte, F., et al. (2019) · Movement Disorders · doi:10.1002/mds.27878 · Cited by 105
Aptasensors for the selective detection of alpha-synuclein oligomer by colorimetry, surface plasmon resonance and electrochemical impedance spectroscopy
Sun, K., Xia, N., Zhao, L., Liu, K., Hou, W., & Liu, L. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.01.171 · Cited by 104
Autophagy in Parkinson’s Disease
Nechushtai, L., Frenkel, D., & Pinkas‐Kramarski, R. (2023) · Biomolecules · doi:10.3390/biom13101435 · Cited by 109
Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status
Koníčková, D., Menšíková, K., Tučková, L., Hényková, E., Strnad, M., Friedecký, D., Stejskal, D., Matěj, R., & Kaňovský, P. (2022) · Biomedicines · doi:10.3390/biomedicines10071760 · Cited by 107
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Han, Q.-Q., & Le, W. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01023-y · Cited by 106
Glymphatic System Dysfunction and Sleep Disturbance May Contribute to the Pathogenesis and Progression of Parkinson’s Disease
Massey, A., Boag, M. K., Magnier, A., Bispo, D. P. C. F., Khoo, T. K., & Pountney, D. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112928 · Cited by 103
The modulatory role of dopamine receptors in brain neuroinflammation
Xia, Q.-P., Cheng, Z.-Y., & He, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105908 · Cited by 87
Enhanced oral bioavailability and neuroprotective effect of fisetin through its SNEDDS against rotenone-induced Parkinson's disease rat model
Kumar, R., Kumar, R., Khurana, N., Singh, S. K., Khurana, S., Verma, S., Sharma, N., Kapoor, B., Vyas, M., Khursheed, R., et al. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111590 · Cited by 81
Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease
Yuan, X., Nie, S., Yang, Y., Liu, C., Xia, D., Meng, L., Xia, Y., Su, H., Zhang, C., Bu, L., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-024-01866-2 · Cited by 86
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Teil, M., Arotçarena, M.-L., Faggiani, E., Laferrière, F., Bézard, E., & Dehay, B. (2020) · Biomolecules · doi:10.3390/biom10030391 · Cited by 80
Cerebrospinal fluid levels of alpha-synuclein measured using a poly-glutamic acid-modified gold nanoparticle-doped disposable neuro-biosensor system
Karaboğa, M. N. S., & Sezgintürk, M. K. (2018) · The Analyst · doi:10.1039/c8an01279b · Cited by 77
Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients
Kang, W., Chen, W., Yang, Q., Zhang, L., Zhang, L., Wang, X., Dong, F., Zhao, Y., Chen, D., Quinn, T. J., et al. (2016) · Scientific Reports · doi:10.1038/srep28143 · Cited by 76
Self-citation
Amyloid Aggregation under the Lens of Liquid–Liquid Phase Separation
Xing, Y., Nandakumar, A., Käkinen, A., Sun, Y., Davis, T. P., Ke, P. C., & Ding, F. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02567 · Cited by 72
Correlation of glymphatic system abnormalities with Parkinson’s disease progression: a clinical study based on non-invasive fMRI
Meng, J., Shen, M.-Q., Lu, Y., Feng, H., Chen, X., Xu, D.-Q., Wu, G.-H., Cheng, Q., Wang, L., & Gui, Q. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12004-6 · Cited by 66
Long Noncoding RNAs in Neurodegenerative Diseases: Pathogenesis and Potential Implications as Clinical Biomarkers
Zhang, M., He, P., & Bian, Z. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.685143 · Cited by 69
α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson’s Disease Patients and Correlate with Disease Severity
Daniele, S., Frosini, D., Pietrobono, D., Petrozzi, L., Gerfo, A. L., Baldacci, F., Fusi, J., Giacomelli, C., Siciliano, G., Trincavelli, M. L., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00053 · Cited by 63
Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson’s Disease
He, S., Wang, F., Yung, K. K. L., Zhang, S., & Qu, S. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00028 · Cited by 62
Biomarkers in Parkinson’s disease: A state of the art review
Yamashita, K. Y., Bhoopatiraju, S., Silverglate, B., & Grossberg, G. T. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100074 · Cited by 62
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 69
Urinary Biomarkers for Neurodegenerative Diseases
Seol, W., Kim, H., & Son, I. (2020) · Experimental Neurobiology · doi:10.5607/en20042 · Cited by 61
Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson’s disease
Ding, J., Zhang, J., Wang, X., Zhang, L., Jiang, S., Yuan, Y., Li, J., Zhu, L., & Zhang, K. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1650-2 · Cited by 62
Self-citation
Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
Wang, Z., Gao, G., Duan, C., & Yang, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108843 · Cited by 62
Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson’s disease
Reyes, J. F., Ekmark-Léwen, S., Perdiki, M., Klingstedt, T., Hoffmann, A., Wiechec, E., Nilsson, P., Nilsson, K. P. R., Alafuzoff, I., Ingelsson, M., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01136-3 · Cited by 59
Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
Lu, R., Zhang, L., & Yang, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1018848 · Cited by 58
Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future
Karaboğa, M. N. S., & Sezgintürk, M. K. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114479 · Cited by 59
Peroxisomal Dysfunction in Neurological Diseases and Brain Aging
Uzor, N.-E., McCullough, L. D., & Tsvetkov, A. S. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00044 · Cited by 61
Cognitive heterogeneity in Parkinson’s disease: A mechanistic view
Carceles‐Cordon, M., Weintraub, D., & Chen‐Plotkin, A. S. (2023) · Neuron · doi:10.1016/j.neuron.2023.03.021 · Cited by 63
Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein
Barkovits, K., Kruse, N., Linden, A., Tönges, L., Pfeiffer, K., Mollenhauer, B., & Marcus, K. (2020) · Cells · doi:10.3390/cells9020370 · Cited by 55
The Systemic Synuclein Sampling Study: Toward a Biomarker for Parkinson’s Disease
Visanji, N. P., Mollenhauer, B., Beach, T. G., Adler, C. H., Coffey, C. S., Kopil, C., Dave, K. D., Foroud, T., Chahine, L. M., Jennings, D. L., et al. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0366 · Cited by 54
Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in PArkiNson Disease (EXPAND) study
Picca, A., Calvani, R., Landi, G., Marini, F., Biancolillo, A., Gervasoni, J., Persichilli, S., Primiano, A., Urbani, A., Bossola, M., et al. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110766 · Cited by 51
DNA repair and neurological disease: From molecular understanding to the development of diagnostics and model organisms
Abugable, A. A., Morris, J. L. M., Palminha, N. M., Zaksauskaite, R., Ray, S., & El‐Khamisy, S. F. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102669 · Cited by 53
Peptide-Imprinted Poly(hydroxymethyl 3,4-ethylenedioxythiophene) Nanotubes for Detection of α Synuclein in Human Brain Organoids
Lee, M., Liu, K.-T., Thomas, J. L., Su, Z.-L., O’Hare, D., van Wuellen, T., Modamio, J., Bolognin, S., Luo, S., Schwamborn, J. C., et al. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c01476 · Cited by 49
The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease
Pawlik, P., & Błochowiak, K. J. (2021) · Diagnostics · doi:10.3390/diagnostics11020371 · Cited by 48
Autophagy‐associated non‐coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis
Hussain, M. S., Moglad, E. H. O., Afzal, M., Sharma, S., Gupta, G., Sivaprasad, G. V., Deorari, M., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14763 · Cited by 47
Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay
Cariulo, C., Martufi, P., Verani, M., Azzollini, L., Bruni, G., Weiss, A., DeGuire, S. M., Lashuel, H. A., Scaricamazza, E., Sancesario, G. M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00889 · Cited by 48
An Electrochemical Immunosensor Based on a Self-Assembled Monolayer Modified Electrode for Label-Free Detection of α-Synuclein
Ge, C., Rahman, M. M., Zhang, W., Lopa, N. S., Jin, L., Yoon, S., Jang, H., Xu, G., & Kim, W. (2020) · Sensors · doi:10.3390/s20030617 · Cited by 47
Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease
François, M., Bull, C. F., Fenech, M. F., & Leifert, W. R. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666181022094924 · Cited by 46
Cerebrospinal fluid biomarker for Parkinson's disease: An overview
Maass, F., Schulz, I., Lingor, P., Mollenhauer, B., & Bähr, M. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.005 · Cited by 44
Protective effect of Indole-3-carbinol, an NF-κB inhibitor in experimental paradigm of Parkinson’s disease: In silico and in vivo studies
Saini, N., Akhtar, A., Chauhan, M., Dhingra, N., & Sah, S. P. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.08.001 · Cited by 43
Fluid biomarkers for the diagnosis of neurodegenerative diseases
Luebke, M., Parulekar, M. S., & Thomas, F. P. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100062 · Cited by 42
Parkinson's disease is an autoimmune disease: A reappraisal
Bonam, S. R., & Muller, S. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102684 · Cited by 42
Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders
Hanif, S., Muhammad, P., Niu, Z., Ismail, M., Morsch, M., Zhang, X., Li, M., & Shi, B. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100008 · Cited by 44
Advances of curcumin in nervous system diseases: the effect of regulating oxidative stress and clinical studies
Wei, Y., Li, H., Li, Y., Zeng, Y., Quan, T., Leng, Y.-E., Chang, E., Bai, Y., Bian, Y., & Hou, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1496661 · Cited by 43
The cervical lymph node contributes to peripheral inflammation related to Parkinson’s disease
Liu, Z., Huang, Y., Wang, X.-J., Li, J.-Y., Zhang, C., Yang, Y., & Zhang, J. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02770-5 · Cited by 33
Self-citation
Serum and Exosomal miR-7-1-5p and miR-223-3p as Possible Biomarkers for Parkinson’s Disease
Citterio, L. A., Mancuso, R., Agostini, S., Meloni, M., & Clerici, M. (2023) · Biomolecules · doi:10.3390/biom13050865 · Cited by 40
Sirtuins as modifiers of Parkinson's disease pathology
Tang, B. L. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23806 · Cited by 41
Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study
Wang, H., Atik, A., Stewart, T., Ginghină, C., Aro, P., Kerr, K. F., Seibyl, J. P., Jennings, D. L., Jensen, P. H., MAREK, K. L., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.04.015 · Cited by 41
Self-citation
Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson’s Disease Patients
Nam, D., Lee, J., Lee, M., Kim, J., Seol, W., Son, I., & Ho, D. H. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-201983 · Cited by 42
Elevated α-synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson’s disease
Lin, C.-W., Lai, T.-T., Chen, S., & Lin, C. (2022) · GeroScience · doi:10.1007/s11357-022-00576-6 · Cited by 40
Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients
Bhumkar, A., Magnan, C., Lau, D., Jun, E. S. W., Dzamko, N. L., Gambin, Y., & Sierecki, E. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202014898 · Cited by 36
Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)
Beach, T. G., Serrano, G. E., Kremer, T., Cañamero, M., Dziadek, S., Sade, H., Derkinderen, P., Corbillé, A.-G., Letournel, F., Muñoz, D. G., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly056 · Cited by 39
Alpha-Synuclein Toxicity on Protein Quality Control, Mitochondria and Endoplasmic Reticulum
Melo, T. Q., Copray, S. C. V. M., & Ferrari, M. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2673-x · Cited by 38
Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients
Youssef, P., Kim, W. S., Halliday, G. M., Lewis, S. J. G., & Dzamko, N. L. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212694 · Cited by 37
The neuromicrobiology of Parkinson’s disease: A unifying theory
Muñoz, M., Empadinhas, N., & Cardoso, S. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101396 · Cited by 38
Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson’s Disease
He, S., Zhong, S., Liu, G., & Yang, J. (2020) · Neurodegenerative Diseases · doi:10.1159/000511083 · Cited by 36
Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson’s Disease
Chung, C., Chan, L., Chen, J., Hung, Y.-C., & Hong, C. (2021) · Biomolecules · doi:10.3390/biom11050744 · Cited by 36
Noradrenergic neuromodulation in ageing and disease
Krohn, F., Lancini, E., Ludwig, M., Leiman, M., Guruprasath, G., Haag, L., Panczyszyn, J., Düzel, E., Hämmerer, D., & Betts, M. J. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105311 · Cited by 41
Potential Exosome Biomarkers for Parkinson’s Disease Diagnosis: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105307 · Cited by 35
Morphometry and Stiffness of Red Blood Cells—Signatures of Neurodegenerative Diseases and Aging
Strijkova, V., Todinova, S. J., Andreeva, T. D., Bogdanova, D., Langari, A., Danailova, A., Krumova, S., Zlatareva, E., Kalaydzhiev, N., Milanov, I. G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010227 · Cited by 35
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
Nwabufo, C. K., & Aigbogun, O. P. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11267-9 · Cited by 37
α-Synuclein Strains and Their Relevance to Parkinson’s Disease, Multiple System Atrophy, and Dementia with Lewy Bodies
Graves, N. J., Gambin, Y., & Sierecki, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512134 · Cited by 36
Electrochemical biosensors for the detection and study of α-synuclein related to Parkinson's disease – A review
Hassan, Q., Li, S., Ferrag, C., & Kerman, K. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.09.013 · Cited by 34
Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.4c09114 · Cited by 38
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy
Pallàs, M., Vázquez, S., Sanfeliu, C., Galdeano, C., & Griñán‐Ferré, C. (2020) · Biomolecules · doi:10.3390/biom10050703 · Cited by 33
A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α-Synuclein in Parkinson’s Disease
Wang, L., Wang, G., Duan, Y., Wang, F., Lin, S., Zhang, F., Li, H., Li, A., & Li, H. (2019) · Neurodegenerative Diseases · doi:10.1159/000506480 · Cited by 31
Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease
Li, X., Li, W., Li, X., Li, X., Sun, L., Yang, W., Cai, Y., Chen, Z., Wu, J., Wang, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.623977 · Cited by 30
Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease
Peng, H., Chen, S., Wu, S., Shi, X., Ma, J., Yang, H., & Li, X. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120730 · Cited by 29
Spinal cord involvement in Lewy body-related α-synucleinopathies
Nardone, R., Höller, Y., Brigo, F., Versace, V., Sebastianelli, L., Florea, C., Schwenker, K., Golaszewski, S. M., Saltuari, L. L., & Trinka, E. (2019) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2018.1557863 · Cited by 28
Potential application of heat shock proteins as therapeutic targets in Parkinson's disease
Guo, H., Yi, J., Wang, F., Lei, T., & Du, H. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105453 · Cited by 26
Exosome α-Synuclein Release in Plasma May be Associated With Postoperative Delirium in Hip Fracture Patients
Yuan, Y., Li, Z., Yang, N., Han, Y., Ji, X., Han, D., Wang, X., Li, Y., Liu, T., Yuan, F., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00067 · Cited by 28
Elevated Serum α-Synuclein Levels in Huntington’s Disease Patients
Breza, M., Emmanouilidou, E., Λεάνδρου, Ε., Kartanou, C., Bougea, A. M., Πάνας, Μ., Stefanis, L., Karadima, G., Vekrellis, K., & Koutsis, G. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.01.037 · Cited by 27
Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease
Henrı́quez, G., & Narayan, M. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00048 · Cited by 27
Parkinson’s Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation
Zoey, F. L., Palanivel, M., Padmanabhan, P., & Gulyás, B. Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707441 · Cited by 27
Salivary alpha‐synuclein as a potential fluid biomarker in Parkinson’s disease: A systematic review and meta‐analysis
Kharel, S., Ojha, R., Bist, A., Joshi, S. P., Rauniyar, R., & Yadav, J. K. (2022) · Aging Medicine · doi:10.1002/agm2.12192 · Cited by 27
Salivary alpha-synuclein (total and oligomeric form): potential biomarkers in Parkinson’s disease
Shaheen, H. A., Sayed, S. S., Mously, S. E., Abuomira, M., & Mansour, M. (2020) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-020-0159-7 · Cited by 27
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease
Si, X., Pu, J., & Zhang, B. (2017) · Journal of Movement Disorders · doi:10.14802/jmd.16061 · Cited by 26
Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson’s Disease
Fričová, D., Harsányiová, J., & Trancikova, A. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228666 · Cited by 29
Point-of-Care Platform for Early Diagnosis of Parkinson’s Disease
Kim, S., Cho, M., & Lee, Y. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01242 · Cited by 26
Rehabilitative Impact of Exercise Training on Human Skeletal Muscle Transcriptional Programs in Parkinson’s Disease
Lavin, K. M., Ge, Y., Sealfon, S. C., Nair, V. D., Wilk, K., McAdam, J. S., Windham, S. T., Kumar, P. L., McDonald, M., & Bamman, M. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00653 · Cited by 23
Positron emission tomography tracers for synucleinopathies
Xiang, J., Zhang, Z., Wu, S., & Ye, K. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00787-9 · Cited by 27
Hydrogen sulphide attenuates neuronal apoptosis of substantia nigra by re‐establishing autophagic flux via promoting leptin signalling in a 6‐hydroxydopamine rat model of Parkinson's disease
Wu, J., Zou, W., Hu, M., Tian, Q., Xiao, F., Li, M., Zhang, P., Chen, Y., & Jiang, J. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13587 · Cited by 25
Structure and function of glycosphingolipids on small extracellular vesicles
He, X. H., Guan, F., & Lei, L. (2022) · Glycoconjugate Journal · doi:10.1007/s10719-022-10052-0 · Cited by 27
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25
Clinical application of circulating microRNAs in Parkinson's disease: The challenges and opportunities as diagnostic biomarker
Yadav, R., Ramaswamy, P., Pal, P. K., & Christopher, R. (2019) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_440_19 · Cited by 24

Authors: Atik, A., Stewart, T., & Zhang, J.
Affiliations: University of Washington (US)
ORCID: Zhang, Jing
Venue: Brain Pathology
Publisher: Wiley
Published: 2016-04-25
Volume: 26
Issue: 3
Pages: 410-418
ISSN: 1015-6305 (ISSN-L)
1750-3639
DOI: 10.1111/bpa.12370
PMC: PMC6245641
OpenAlex: W2289901196
Cited by: 311
References: 119
Citations by year: 2026: 25 · 2025: 42 · 2024: 36 · 2023: 42 · 2022: 36 · 2021: 42 · 2020: 40 · 2019: 15 · 2018: 13 · 2017: 12 · 2016: 7
FWCI: 2.17
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Brain Pathology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (NIH) (U01 NS082137, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords: alpha-synuclein, Parkinson's disease, biomarkers, Lewy bodies, early diagnosis, disease progression monitoring, cerebrospinal fluid, plasma, blood, saliva, combined biomarkers, neurodegeneration
MeSH terms: Humans, Parkinson Disease, Biomarkers, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alpha‐Synuclein as a Biomarker for Parkinson's Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks